Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) will report results from three
organ impairment clinical trials after market close on Thursday, January
8. The stock price soared $1.70 to $9.79.
Conatus to report study results
January 05, 2015 at 12:08 PM EST
